Michael Etscheid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Etscheid has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Johannes Dodt
Paul-Ehrlich-Institute, Department of Haematology/Transfusion Medicine, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany
3 shared publicationsRainer Seitz
Paul-Ehrlich-Institute, Department of Haematology/Transfusion Medicine, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany
3 shared publicationsJ. Dodt
Department of Haematology/Transfusion Medicine, Paul Ehrlich Institute, Langen, Germany
2 shared publicationsJulia Anne Kreß
Department of Haematology and Transfusion Medicine, Paul-Ehrlich-Institute, Federal Agency for Sera and Vaccines, D-63225 Langen, Germany
2 shared publicationsA. Hunfeld
Department of Haematology/Transfusion Medicine, Paul Ehrlich Institute, Langen, Germany
1 shared publicationJulia Kreß
Paul-Ehrlich-Institute, Department of Haematology/Transfusion Medicine, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany
1 shared publication
Latest Publications
- 5 May 2011
- Published by Wiley in Vox Sanguinis
- Vol. 102 (1) , 40-46
Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products
Background and Objectives The occurrence of thromboembolic events (TEEs) with intravenous immunoglobulin lots (IVIGs) raised the question of the causative agent for these adverse events. We investigated the predominant plasma proteases in 19 IVIG lots from five manufacturers including three lots associated with adverse events.Material and Methods The inhibitor profile of the amidolytic activity in IVIG lots was investigated with substrates S‐2302 and S‐2288. In immunocapture assays, prekallikrein and FXI antigen and respective active proteases were quantified. Non‐activated partial thromboplastin time (NAPTT) and a modified FXIa PTT served as global and FXIa‐specific clotting assays, respectively.Results Kallikrein was identified as one major contaminant activity in IVIGs. A second activity was seen in some IVIGs with substrate S‐2288, but not with S‐2302. Inhibition studies excluded FXIIa, thrombin or plasmin as contaminant activity. FXI antigen was seen in all 19 IVIG lots, and FXIa activity was found as second major impurity in some IVIGs, including all lots involved in TEEs. FXIa highly correlated with a short clotting time in NAPTT.Conclusions Kallikrein and FXIa are the major contaminants in IVIGs. FXIa was highly procoagulant, with highest level in TEE‐associated IVIGs. Since the NAPTT unambiguously identified FXIa procoagulant activity in IVIGs, its implementation as a release test would improve the safety of IVIGs.
- 5 May 2011
- Published by Wiley in Vox Sanguinis
- Vol. 102 (1) , 40-46
Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products
Background and Objectives The occurrence of thromboembolic events (TEEs) with intravenous immunoglobulin lots (IVIGs) raised the question of the causative agent for these adverse events. We investigated the predominant plasma proteases in 19 IVIG lots from five manufacturers including three lots associated with adverse events.Material and Methods The inhibitor profile of the amidolytic activity in IVIG lots was investigated with substrates S‐2302 and S‐2288. In immunocapture assays, prekallikrein and FXI antigen and respective active proteases were quantified. Non‐activated partial thromboplastin time (NAPTT) and a modified FXIa PTT served as global and FXIa‐specific clotting assays, respectively.Results Kallikrein was identified as one major contaminant activity in IVIGs. A second activity was seen in some IVIGs with substrate S‐2288, but not with S‐2302. Inhibition studies excluded FXIIa, thrombin or plasmin as contaminant activity. FXI antigen was seen in all 19 IVIG lots, and FXIa activity was found as second major impurity in some IVIGs, including all lots involved in TEEs. FXIa highly correlated with a short clotting time in NAPTT.Conclusions Kallikrein and FXIa are the major contaminants in IVIGs. FXIa was highly procoagulant, with highest level in TEE‐associated IVIGs. Since the NAPTT unambiguously identified FXIa procoagulant activity in IVIGs, its implementation as a release test would improve the safety of IVIGs.
- 29 February 2008
- Published by Elsevier in International Immunopharmacology
- Vol. 8 (2) , 166-170
The hyaluronic acid-binding protease: A novel vascular and inflammatory mediator?
- 29 February 2008
- Published by Elsevier in International Immunopharmacology
- Vol. 8 (2) , 166-170
The hyaluronic acid-binding protease: A novel vascular and inflammatory mediator?
- 1 January 2006
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 387 (9) , 1275-1283
Induction of intracellular signalling in human endothelial cells by the hyaluronan-binding protease involves two distinct pathways
Recently a novel plasma serine protease with high affinity to hyaluronic acid and glycosaminoglycans, such as heparin and heparan sulfate, has been described and termed hyaluronan-binding protease (HABP). HABP cleaves kininogen in vitro, releasing the vasoactive peptide bradykinin, and activates plasminogen activators, suggesting a vascular cell-directed physiological function of this novel plasma protease. Here we show that HABP stimulates human umbilical vein endothelial cells (HUVECs) by activating two distinct cell-surface receptors. On the one hand, HABP releases bradykinin from cell surface-bound or soluble kininogen and triggers a bradykinin B2-receptor-dependent mobilisation of intracellular Ca2+. On the other hand, HABP activates the p44/42-dependent MAPK (ERK1/2) signalling cascade independent of the B2-receptor, but involving the fibroblast growth factor receptor-1 and basic fibroblast growth factor. This signalling pathway leads to phosphorylation of the kinases Raf, MEK1/2 and ERK1/2. The extracellular activity of HABP also affects the gene expression level through phosphorylation of two transcription factors, the cAMP-responsive element binding protein CREB and the proto-oncogene c-Myc. Our results indicate a proangiogenic potential of HABP, which, in combination with a profibrinolytic activity, directs the physiological function of this plasma protease to processes in which clot lysis, cell motility and neovascularisation are pivotal processes, e.g., in wound healing, tissue repair and tumour progression.
- 1 January 2006
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 387 (9) , 1275-1283
Induction of intracellular signalling in human endothelial cells by the hyaluronan-binding protease involves two distinct pathways
Recently a novel plasma serine protease with high affinity to hyaluronic acid and glycosaminoglycans, such as heparin and heparan sulfate, has been described and termed hyaluronan-binding protease (HABP). HABP cleaves kininogen in vitro, releasing the vasoactive peptide bradykinin, and activates plasminogen activators, suggesting a vascular cell-directed physiological function of this novel plasma protease. Here we show that HABP stimulates human umbilical vein endothelial cells (HUVECs) by activating two distinct cell-surface receptors. On the one hand, HABP releases bradykinin from cell surface-bound or soluble kininogen and triggers a bradykinin B2-receptor-dependent mobilisation of intracellular Ca2+. On the other hand, HABP activates the p44/42-dependent MAPK (ERK1/2) signalling cascade independent of the B2-receptor, but involving the fibroblast growth factor receptor-1 and basic fibroblast growth factor. This signalling pathway leads to phosphorylation of the kinases Raf, MEK1/2 and ERK1/2. The extracellular activity of HABP also affects the gene expression level through phosphorylation of two transcription factors, the cAMP-responsive element binding protein CREB and the proto-oncogene c-Myc. Our results indicate a proangiogenic potential of HABP, which, in combination with a profibrinolytic activity, directs the physiological function of this plasma protease to processes in which clot lysis, cell motility and neovascularisation are pivotal processes, e.g., in wound healing, tissue repair and tumour progression.
- 1 December 2005
- Published by Elsevier in Cellular Signalling
- Vol. 17 (12) , 1486-1494
The hyaluronan-binding protease upregulates ERK1/2 and PI3K/Akt signalling pathways in fibroblasts and stimulates cell proliferation and migration
- 1 December 2005
- Published by Elsevier in Cellular Signalling
- Vol. 17 (12) , 1486-1494
The hyaluronan-binding protease upregulates ERK1/2 and PI3K/Akt signalling pathways in fibroblasts and stimulates cell proliferation and migration
- 1 January 2004
- Published by Elsevier in European Journal of Cell Biology
- Vol. 82 (12) , 597-604
Inhibition of bFGF/EGF-dependent endothelial cell proliferation by the hyaluronan-binding protease from human plasma
- 1 January 2004
- Published by Elsevier in European Journal of Cell Biology
- Vol. 82 (12) , 597-604
Inhibition of bFGF/EGF-dependent endothelial cell proliferation by the hyaluronan-binding protease from human plasma